Tamoxifen (Hexal)


What it is used for

Treatment of breast cancer. TAMOXIFEN SANDOZ is indicated for the treatment of breast cancer.,Primary reduction of breast cancer risk TAMOXIFEN SANDOZ is indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).


How to take it

The way to take this medicine is: Oral. This medicine is taken by mouth.

  • Store below 25 degrees Celsius
  • Protect from Light
  • Protect from Moisture
  • Shelf lifetime is 3 Years.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.


Reporting side effects

You can help ensure medicines are safe by reporting the side effects you experience.

You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems


How to take it

The way to take this medicine is: Oral. This medicine is taken by mouth.

  • Store below 25 degrees Celsius
  • Protect from Light
  • Protect from Moisture
  • Shelf lifetime is 3 Years.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.


Pregnant or planning a pregnancy?

For the active ingredient tamoxifen

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.


Do I need a prescription?

We are unable to tell you if you need a prescription for this medicine. You can ask your pharmacist.This medicine is Not Scheduled.


Visual appearance

White, round, biconvex tablets with a score notch on one side.

Images are the copyright of the Pharmacy Guild of Australia

0 0 votes
Do you use this medicine? Rate it:
Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments